Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SOD1 | P00441 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934890 | 0.86 | MAOB (0.49) | MAOBRAB9AHTTL3MBTL1SOD1 | |
| SCHEMBL2794321 | 0.81 | MAOB (0.51) | MAOBRAB9AHTTL3MBTL1ALDH1A1 | |
| SCHEMBL4349792 | 0.81 | MAOB (0.55) | MAOBRAB9AHTTL3MBTL1SOD1 | |
| SCHEMBL5485783 | 0.81 | MAOB (0.55) | MAOBRAB9AHTTL3MBTL1SOD1 | |
| SCHEMBL14241245 | 0.80 | MAOB (0.50) | MAOBRAB9AHTTL3MBTL1SOD1 | |
| SCHEMBL31168037 | 0.79 | SOD1 (0.39) | MAOBSOD1 | |
| SCHEMBL14027336 | 0.79 | ALDH1A1 (0.54) | MAOBHSD17B10ALDH1A1KDM4ELMNA | |
| SCHEMBL4164639 | 0.78 | HCRTR1 (0.42) | MAOBALDH1A1 | |
| SCHEMBL9324039 | 0.78 | MAOB (0.51) | MAOBHSD17B10ALDH1A1KDM4ELMNA | |
| SCHEMBL19384259 | 0.78 | LMNA (0.61) | MAOBHSD17B10ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970215-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | MAOB 3305/4885RAB9A 3327/4885HTT 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.